Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sabcomeline SCHEMBL3843721 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3838658 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL3133982 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL7076525 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL7079710 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6392265 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL34463221 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL18049048 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6629873 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| Sabcomeline SCHEMBL6629868 | 0.98 | CHRM2 (0.97) | CHRM2CHRM4CHRM1CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1104301-B1 | Treatment of psychosis or neuropsychiatric symptoms associated with Alzheimer's Disease | MINSTER PHARMACEUTICALS PLC (GB) | 2009-10-07 | — | — | EP | claimed |
| US-20050085525-A1 | Method of treatment | SMITHKLINE BEECHAM, P.L.C. | 2005-04-21 | — | — | US | claimed |
| EP-1104301-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2004-09-15 | — | — | EP | claimed |
| US-20040147583-A1 | Method of treatment | SMITHKLINE BEECHAM P.L.C | 2004-07-29 | — | — | US | claimed |
| US-6750227-B2 | ADMINISTERING TO THE PATIENT (R-(Z))-ALPHA-(METHOXYIMINO)-ALPHA -(1-AZABICYCLO(2.2.2)OCT-3-YL) ACETONITRILE OR A PHARMACEUTICALLY ACCEPTABLE SALT FOR TREATING PSYCOSIS OR NEUROPSYCHIATRIC SYMPTOMS | SMITHKLINE BEECHAM CORPORATION | 2004-06-15 | — | — | US | claimed |
| US-20030166703-A1 | Method of treatment | SMITH KLINE BEECHAM P.L.C. (GB) | 2003-09-04 | — | — | US | claimed |
| EP-0759921-B1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2003-07-09 | — | — | EP | claimed |
| US-20030125353-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION & SMITHKLINE BEECHAM P.L.C. | 2003-07-03 | — | — | US | claimed |
| US-20020156093-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION & SMITHKLINE BEECHAM P.L.C. | 2002-10-24 | — | — | US | claimed |
| EP-0918521-B1 | FORMULATION FOR THE TREATMENT AND/OR PROPHYLAXIS OF DEMENTIA | SMITHKLINE BEECHAM PLC (GB) | 2002-09-25 | — | — | EP | claimed |
| US-20020127271-A1 | Formulation for the treatment and/or prophylaxis of dementia | SMITHKLINE BEECHAM P.L.C. | 2002-09-12 | — | — | US | claimed |
| EP-0786998-B1 | USE OF R-(Z)]-ALPHA-(METHOXYIMINO)-ALPHA-(1-AZABICYCLO 2.2.2] OCT-3-YL) ACETONITRILE TO REDUCE AMYLOID BETA A4 FORMATION IN ALZHEIMER'S DISEASE | SMITHKLINE BEECHAM PLC (GB) | 2002-03-27 | — | — | EP | claimed |
| EP-1104301-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-06 | — | — | EP | claimed |
| WO-2000003717-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-27 | — | — | WO | claimed |
| US-8865641-B2 | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865641-B2 | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120322719-A1 | METHODS OF TREATMENT OF FATTY LIVER DISEASE BY PHARMACOLOGICAL ACTIVATION OF CHOLINERGIC PATHWAYS | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-12-20 | — | — | US | disclosed |
| EP-0759921-A1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1997-03-05 | — | — | EP | disclosed |
| WO-1997004750-A2 | PROCESS FOR PREPARING SOLID DOSAGE FORMS OF VERY LOW-DOSE DRUGS | SMITHKLINE BEECHAM PLC (GB) | 1997-02-13 | — | — | WO | disclosed |
| WO-1995031456-A1 | PROCESS FOR THE PREPARATION OF AZABICYCLIC DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322719-A1 | METHODS OF TREATMENT OF FATTY LIVER DISEASE BY PHARMACOLOGICAL ACTIVATION OF CHOLINERGIC PATHWAYS | CHAT, CHKB, CHRM2 | CHRM2 3/4885CHRM4 7/4885CHRM1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.